Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NUjZW3k5S2WubDDWbYFjcWyrdImgRZN{[Xl? MlzFNk42NTF3IH7N NYTUVGJzPzJiaB?= NY\MW3dncW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NHjYSXQzPTd7MEmwOy=>
U2932  NVniUIF5S2WubDDWbYFjcWyrdImgRZN{[Xl? MV6yMlUuOTVibl2= NUnycpd6PzJiaB?= NEPu[GVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NUXFc5ZyOjV5OUC5NFc>
OCI-LY7 MoLNR4VtdCCYaXHibYxqfHliQYPzZZk> NUP1SmNmOi53LUG1JI5O NGPPOJg4OiCq MojabY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NHH6dGwzPTd7MEmwOy=>
Farage MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYWyMlUuOTVibl2= NYDn[mFZPzJiaB?= NHu5OXRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MWCyOVc6ODlyNx?=
LY7/EBV M1;5OWNmdGxiVnnhZoltcXS7IFHzd4F6 MW[yMlUuOTVibl2= NVT1b5RSPzJiaB?= MX3pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M2XFUlI2PzlyOUC3
U2932/EBV M2TN[WNmdGxiVnnhZoltcXS7IFHzd4F6 NVmz[2o{Oi53LUG1JI5O M3;LS|czKGh? MX3pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NYG1NpZnOjV5OUC5NFc>
HCT116 M2XVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDhRlk2NTVyMECgcm0> MWGyOEBp NHvwZpBFVVOR NUTtTmlpcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MmPRNlU1QTJ3MUW=
ACH-2 MY\GeY5kfGmxbjDBd5NigQ>? M4nB[FEuQSCwTR?= Ml7CNlQhcA>? M17tb4lv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> MlLmNlUyPDl2Nke=
MCF-10A NHPRWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfSdmZZUUN3ME2wMlE4yrFyLkCxJI5O NGjWb40zPDl3NEi1Oi=>
MCF-7 M3LteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMUFCtVAvOjBibl2= NYf6RnZ{OjR7NUS4OVY>
SK-BR-3 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjUWIVKSzVyPUGuNFDDuTBwM{Wgcm0> MYCyOFk2PDh3Nh?=
MDA-MB-231 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfnO2RKSzVyPUCuOljDuTBwMUSgcm0> NYnQO2tQOjR7NUS4OVY>
PC3 M1nLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrCdYhKSzVyPUGuOlXDuTBwM{Wgcm0> NIXpdFAzPDl3NEi1Oi=>
HCT116 NH;FNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\tZ2lEPTB;MT6wNOKyOC5yMDDuUS=> Ml3QNlQ6PTR6NU[=
HCT116-p21-/- NWXKPHM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2frbmlEPTB;MT6yOuKyOC5|NzDuUS=> Mn\SNlQ6PTR6NU[=
S1 M{T6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;yTIhzUUN3ME23MlY4yrFyLkK5JI5O Moi1NlQ6PTR6NU[=
SW620 NYXYdFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0WXFxUUN3ME2wMlk{yrFyLkK5JI5O M3zwO|I1QTV2OEW2
LOX-IMVI NFX2d|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\r[GlEPTB;MD64O:KyOC5yMzDuUS=> Mn3lNlQ6PTR6NU[=
UACC-62 M3P2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwNUdCtVAvOTZibl2= M{\jdlI1QTV2OEW2
MDA-MB-435 NFL3doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfoZplGUUN3ME2wMlkxyrFyLkC2JI5O MVGyOFk2PDh3Nh?=
SF-295 NFLtfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7vXoFKSzVyPUCuPFjDuTBwMUWgcm0> MVOyOFk2PDh3Nh?=
A549 NWP5TYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LBe2lEPTB;MT6yOuKyOC5{NDDuUS=> NVzzWY9[OjR7NUS4OVY>
H460 M3fYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwNUlCtVAvQDBibl2= NHLLOoEzPDl3NEi1Oi=>
EKVX Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOwTWZKSzVyPUGuN|PDuTBwM{Sgcm0> Ml7yNlQ6PTR6NU[=
H146 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vk[WlEPTB;MD6yNuKyOC5yNzDuUS=> MYGyOFk2PDh3Nh?=
H526 NUPhS5p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TSN2lEPTB;MD6xOeKyOC5yMzDuUS=> M{DMVlI1QTV2OEW2
HuT-78 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIflcXVKSzVyPUGuO|PDuTBwNESgcm0> M{e1[|I1QTV2OEW2
HA NGnB[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPUnYxNjZ{NT2xNI5O MnHhOFghcA>? MkHGbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> Mke0NlQ4PzF3MUC=
MS-275 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmwMlYzPS1zMH7N M3fhbFQ5KGh? NF7WcXhqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? M4XDelI1PzdzNUGw
CD4 T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi0PEBp M3n3TmVEPTB;ND61xtEyNjBibl2= MWOyOFczOjR3NB?=
CD4 T NFzpcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvoOFghcA>? NVO5co1rS0N3ME2xNFfDuTF{NjDuUS=> MUWyOFczOjR3NB?=
CD4+ T M1vaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv6S4dGSzVyPUOgcm0> M3\PclI1PDl3MUC1
A549 NEPrT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXlNVDjiJNzMEFCpI5O NGfiXHgzPC9|Nj:0PEBp NYfs[oJqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MW[yOFQ5PTd7OR?=
JJN3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[yOE81QCCq NWHNRXNiTUN3MEyx5qCKdk19IES45qCKcA>? NFTMToUzPDB|MEG1NC=>
OPM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LoblI1NzR6IHi= NUDIVYFkTUN3MIO9NgKBkW6POzC0PQKBkWh? NVThUop3OjRyM{CxOVA>
RPMI-8226 NYf2PWZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiyOE81QCCq NG\Z[|hGSzVyc{2xMljjiImwTUugOFjjiImq NIrZXWozPDB|MEG1NC=>
U266 M4DEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37IfFI1NzR6IHi= M2LkfmVEPTC|PUGw5qCKdk19IES45qCKcA>? NEPURmYzPDB|MEG1NC=>
CA46 MYXBdI9xfG:|aYOgRZN{[Xl? Mn\wOkBp NHflZXVqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NEi2R4ozOzl4NkG2OC=>
DG75 M4Wzc2Fxd3C2b4Ppd{BCe3OjeR?= NUCxTFdmPiCq M3;oOYlv\HWlZYOgco8h[XCxcITvd4l{ MV2yN|k3PjF4NB?=
Ramos NWPTU2Q{SXCxcITvd4l{KEG|c3H5 NHXkcGs3KGh? NWHTcWFmcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MWiyN|k3PjF4NB?=
ST486 NH\aWmJCeG:ydH;zbZMhSXO|YYm= NWXlfG11PiCq MoLObY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz MYqyN|k3PjF4NB?=
HuT78 M{D4XmFxd3C2b4Ppd{BCe3OjeR?= MUCxM|ExNzFyMDDuUS=> NVPuTJhrPDhiaB?= MlHpbY5lfWOnczDhdI9xfG:|aYOgZZQhOSCwTR?= NVLnOVR6OjN3M{K3N|I>
DpVp35 Mnn0RZBweHSxc3nzJGF{e2G7 NEHIPGUyNzFyL{GwNEBvVQ>? NXXiT3FGPDhiaB?= NIXuPXJqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M1[2fVI{PTN{N{Oy
DpVp50 MYTBdI9xfG:|aYOgRZN{[Xl? NGfPWFEyNzFyL{GwNEBvVQ>? NHnKN3g1QCCq M2W2TYlv\HWlZYOgZox2dnRiYYDvdJRwe2m| M2nEdlI{PTN{N{Oy
DpP75  MmXFRZBweHSxc3nzJGF{e2G7 NUHycm8{OS9zMD:xNFAhdk1? MmjyOFghcA>? NYfPZ2J2cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= M1zHSFI{PTN{N{Oy
SKOV-3 NG\1dHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zYW|HjiJN{MH7N NIfiTG44OiCq MVrEUXNQ MWjy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NWrISHc3OjNyMUCzOFg>
Brca1 WT NV3HNnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TUUlHjiJN{MH7N M2D2[|czKGh? MmPMSG1UVw>? MmPzdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> Mk\2NlMxOTB|NEi=
Brca1 Null MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKxNgKBmzJybl2= M13KUFczKGh? NFjRV|FFVVOR NILmR4xz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M3L0SlI{ODFyM{S4
OVCAR-8  M4jDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDvNlEy6oDVMkDuUS=> M1;CR|czKGh? MYPEUXNQ NGTXXVJz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NFTKNJUzOzBzMEO0PC=>
NCI/ADR-RES NVr5VVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ESFHjiJN{MH7N MV:3NkBp MWXEUXNQ NWj3b2kzemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MoruNlMxOTB|NEi=
HCT116 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe1JI5ONTVyIN88US=> NEHaRYQzPCCq Mn;6SG1UVw>? M4POUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MmGzNlI6OjR7NUi=
RKO M1vzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrGb49EPSCwTT21NEDPxE1? MoTlNlQhcA>? NIfrNIdFVVOR NH;rdG1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXeyNlkzPDl3OB?=
CO115 NFq3NYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq2fpY6PSCwTT21NEDPxE1? M4njd|I1KGh? M4nrdmROW09? NF\rdYxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFXRNWgzOjl{NEm1PC=>
HFS M1SxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi1JI5O NUfQRplVOjRxNEivO|IhcA>? NYX5ZYU4cW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NUjWPHB7OjJzME[yPFI>
LNCaP MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly2OUBvVQ>? NHnLd|QzPC92OD:3NkBp NVHPdHRFcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? MknPNlIyODZ{OEK=
A549 M3;BO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP2fGUzPSCwTR?= NV;1TpRkOjRxNEivO|IhcA>? NXz5RXBYcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? MWOyNlExPjJ6Mh?=
697  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL4O|lKSzVy4pEJQgKBkTJwNdMgcm0> NV;nNYdNOjF3M{iyNVY>
697-R NYLMNHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fycGlEPTEkgJm95qCKQC54wrDuUeKh MkHXNlE2Ozh{MU[=
HUT78 NF;CUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFibl2= MWqyNVE6QDV2NR?=
THJ-16T MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[0NXAyKG6P Mm[3NlQhcA>? M2G1V4lvcGmkaYTzJINmdGxiZ4Lve5Rp MVeyNFgyODV4OB?=
HCT116 MWrGeY5kfGmxbjDBd5NigQ>? MV2yNEBvVQ>? NWfSfo9HQCCq MVftc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? MWCyNFc{QTR3NB?=
B104  NIHESm9HfW6ldHnvckBCe3OjeR?= NYPGSYdvOiCwTR?= M2DoflI1NzR6L{eyJIg> NXH1OoJFcW6lcnXhd4V{KHSqZTDzeZJn[WOnIHX4dJJme3Orb36gc4YhS0R{MNMg MY[yNFY5PjVyNR?=
HL-60  MmLGR5l1d3SxeHnjbZR6KEG|c3H5 MofINU02ODBibl2= NYnvZoFEOjRiaB?= MmS4bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M1zXbFIxPjJ2MU[z
HP100 M1jlbGN6fG:2b4jpZ4l1gSCDc4PhfS=> NIDxOJgyNTVyMDDuUS=> MlLKNlQhcA>? NVPINJFUcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NYe3O3E4OjB4MkSxOlM>
HL-60  MW\GeY5kfGmxbjDBd5NigQ>? M1HVcFExKG6P M3PTXlQwPi9zNjDo M1;CUIlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= Mn7XNlA3OjRzNkO=
HP100 NGrrOXFHfW6ldHnvckBCe3OjeR?= M3XJUFExKG6P M1;3b|QwPi9zNjDo NITB[IxqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= MYiyNFYzPDF4Mx?=
HL-60  M2DMPGZ2dmO2aX;uJGF{e2G7 MYmxNE02ODBibl2= NFrMNGI1KGh? MojW[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi MofWNlA3OjRzNkO=
HP100 MXjGeY5kfGmxbjDBd5NigQ>? M{ixfVExNTVyMDDuUS=> NUTEUo1WPCCq MUjk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MWeyNFYzPDF4Mx?=
11z MnO4T4lv[XOnIFHzd4F6 MUKzMVExOCCwTR?= NFfHUWtz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= MlG3NlA3ODVzNES=
SKOV-3 NXmxdJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2OE85NzF4IH7N MkjUOFghcA>? M1LpfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NEnkVGkzODRyNEW2OC=>
OVCAR-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LlUVQwQC9zNjDuUS=> M1\6cFQ5KGh? MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M3HyV|IxPDB2NU[0
HBL-2 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\CVlIuOTBibl2= NYr5U5drOjRiaB?= NV\ENZE1UUN3ME20MlMhdk1? M4nVSlIxODZ6MEiw
Jeko-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSyMVUxKG6P MnK0NlQhcA>? M4i2OGlEPTB;MUGgcm0> M17iU|IxODZ6MEiw
Granta-519 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M336UVUuPDBibl2= MVWyOEBp NX;USGRWUUN3ME21PE42KG6P NVLX[I1qOjByNkiwPFA>
L1236 NX3COI1JS3m2b4TvfIlkcXS7IFHzd4F6 MX6xJI5ONTFyMDFOwG0> NXvMfIxSPDhiaB?= NWHTTZhxTUN3ME2wMlA4KM7:TR?= NWDRTlRPOTl{M{O0O|A>
L428 NFjUdVJEgXSxdH;4bYNqfHliQYPzZZk> NXe0e3FqOSCwTT2xNFAh|ryP M3nnPVQ5KGh? MlrRSWM2OD1yLkSzJO69VQ>? NILZVmkyQTJ|M{S3NC=>
KM-H2 MYrDfZRwfG:6aXPpeJkhSXO|YYm= NYDGeIl5OSCwTT2xNFAh|ryP NF;BZlg1QCCq NFvOSFlGSzVyPUCuOVgh|ryP M{fMbFE6OjN|NEew
L540Cy NFfITo9EgXSxdH;4bYNqfHliQYPzZZk> NHO2U|kyKG6PLUGwNEDPxE1? MkjCOFghcA>? NHPSfXVGSzVyPUCuNVYh|ryP MVKxPVI{OzR5MB?=
G401 MWHGeY5kfGmxbjDBd5NigQ>? MlizNVAhdk1? NGTib2kzPC92OD:3NkBp Mn[ySG1UVw>? MnvEbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NUDoRXlZOTl{MkG1PFY>
STM91-01 MYrGeY5kfGmxbjDBd5NigQ>? M2O4W|ExKG6P MXyyOE81QC95MjDo NH6yTYlFVVOR NWLST4pkcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MYOxPVIzOTV6Nh?=
SJSC  MkezSpVv[3Srb36gRZN{[Xl? NUDjS|ljOTBibl2= M{XQU|I1NzR6L{eyJIg> MkOzSG1UVw>? MU\pcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M{jXSlE6OjJzNUi2
BT16  M4\ac2Z2dmO2aX;uJGF{e2G7 M3\PNlExKG6P NX3VVmZnOjRxNEivO|IhcA>? NXvnNYRLTE2VTx?= M2PT[Ylv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MV2xPVIzOTV6Nh?=
NCI-H1299 NXLmO4wxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwNtMxNE4zKG6pL33s M{fjU|E6OTd7OEmw
NCI-2882 NEDCeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6TWM2OD1zLkdCtVAvODRibnevcYw> MX2xPVE4QTh7MB?=
HCC95 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwNdMxNE4xPSCwZz;tcC=> M{HKeVE6OTd7OEmw
NCI-H23 NUTlVVRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzE[lFFUUN3ME2yMlnDuTBwMjDu[{9udA>? MV[xPVE4QTh7MB?=
NCI-H157 NF;wNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7weolKSzVyPUGuOuKyOC5yMjDu[{9udA>? MorSNVkyPzl6OUC=
NCI-H460 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1{LkJCtVAvODdibnevcYw> NVnxVWJkOTlzN{m4PVA>
NCI-H1975 NG[3O|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[ydmFIUUN3ME2xMlPDuTBwMESgcocwdWx? NEDUZoIyQTF5OUi5NC=>
NCI-H820 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\xTWM2OD1{LkVCtVAvOSCwZz;tcC=> NGPzcWoyQTF5OUi5NC=>
NCI-H1650 NUnSOJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDid|BKSzVyPUSuPeKyOC5|IH7nM41t MWWxPVE4QTh7MB?=
DTC1 NX\wfpJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNUGgcm0> NVPTR2JwOTh3Nk[yOFY>
KAO NY\Oe5V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2Z2k2UUN3ME2wMlkyKG6P M4n3OVE5PTZ4MkS2
SU-CCS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGzb3hKSzVyPUCuPFkhdk1? MYGxPFU3PjJ2Nh?=
SYO-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNkegcm0> NWjhVmNiOTh3Nk[yOFY>
FUJI MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17rb2lEPTB;MT6zNUBvVQ>? NHTTeYsyQDV4NkK0Oi=>
SKNMC NUTKUHl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\WfZZKSzVyPUGuNVchdk1? MmfiNVg2PjZ{NE[=
402-91 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMk[gcm0> NInCSHIyQDV4NkK0Oi=>
1765-92 M4W0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwN{egcm0> NV\NWXVWOTh3Nk[yOFY>
JN-DSRCT-1 NIG4U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PTWmlEPTB;MT6yOUBvVQ>? M4jRSlE5PTZ4MkS2
NMS-2PC NGrZd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nSZ2lEPTB;MD64NUBvVQ>? Mnm2NVg2PjZ{NE[=
HL60 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW1fZU2UUN3ME2xMlg3KG6P M1TH[lE5PTZ4MkS2
A549 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwMkSgcm0> MY[xPFU3PjJ2Nh?=
SW480 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfEXoYzUUN3ME2yMlY6KG6P NFzIV4syQDV4NkK0Oi=>
MCF7 M{HwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwNUWgcm0> M2nqeFE5PTZ4MkS2
PC-3 NETlbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDFTWM2OD1{LkWxJI5O NEjCXpAyQDV4NkK0Oi=>
MMRU MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHjbHJKSzVyPUKuOVchdk1? NFHscJoyQDV4NkK0Oi=>
Hs68 NIH5T|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PGcGlEPTB;PkGwJI5O M1eyTFE5PTZ4MkS2
hMSC-001F NWnvV|RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfIRoQzUUN3ME2+NVAhdk1? MWWxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID